KR20030083159A - Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract - Google Patents
Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract Download PDFInfo
- Publication number
- KR20030083159A KR20030083159A KR1020020021590A KR20020021590A KR20030083159A KR 20030083159 A KR20030083159 A KR 20030083159A KR 1020020021590 A KR1020020021590 A KR 1020020021590A KR 20020021590 A KR20020021590 A KR 20020021590A KR 20030083159 A KR20030083159 A KR 20030083159A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- treatment
- prevention
- male hormone
- turmeric extract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 5α-환원효소(reductase)의 활성 억제 작용을 갖는 울금(鬱金, Curcuma longa) 추출물을 포함하는 조성물에 관한 것으로, 더욱 상세하게는 5α-환원효소에 의한 디히드로테스토스테론의 과잉생산을 억제하여 남성호르몬 의존형 피부질환의 예방 및 치료에 효과적인 울금 추출물을 포함하는 조성물에 관한 것이다.The present invention relates to a composition comprising an extract of Curcuma longa having an activity of inhibiting the activity of 5α-reductase, and more particularly, inhibits overproduction of dihydrotestosterone by 5α-reductase. It relates to a composition comprising turmeric extract effective to prevent and treat male hormone-dependent skin diseases.
여드름, 남성형 탈모, 지루성피부염 등은 남성호르몬 의존성(androgen-dependent disorders) 만성피부질환이다(Van Luu-The 외 5인; Characterization, Expression, and Immunohistochemical Localization of 5α-Reductase in Human Skin,J. Invest. Dermatol, 102, 221-226, 1994). 그 중 남성형 탈모는 남성 호르몬의 양에 직접적으로 관계되며, 이에 따라 남성호르몬 활성 억제를 통한 탈모를 예방하고 치료하기 위한 많은 연구가 진행되어 왔다.Acne, androgenetic alopecia, seborrheic dermatitis, etc. are chronic skin diseases with androgen-dependent disorders (Van Luu-The et al. 5; Characterization, Expression, and Immunohistochemical Localization of 5α-Reductase in Human Skin, J. Invest. Dermatol , 102, 221-226, 1994). Among them, androgenetic alopecia is directly related to the amount of androgen hormones, and thus, many studies have been conducted to prevent and treat hair loss by inhibiting androgen activity.
또한 만성피부질환 중 여드름과 지루성피부염은 남성호르몬에 의해 생성된 과잉의 피지에 의해서 발병하는 피지관련질환(sebum-related disorders)으로, 근본적인 치료를 위해서는 남성호르몬의 활성 억제를 통하여 피지의 과잉 생성을 억제하여야 한다.In addition, acne and seborrheic dermatitis in chronic skin diseases are sebum-related disorders caused by excess sebum produced by male hormones. For fundamental treatment, sebum overproduction is suppressed through inhibition of male hormone activity. It must be restrained.
남성호르몬의 작용을 피지생성 기전과 연관하여 간략히 설명하면 다음과 같다. 남성호르몬 중의 하나인 테스토스테론(testosterone)은 5α-환원효소에 의하여 활성 남성호르몬인 디히드로테스토스테론(dihydrotestosterone)으로 전환되는데, 이 호르몬의 비정상적인 과잉 작용은 남성형 탈모를 야기하는 물질로 작용하면서 동시에 피지세포(sebocyte)에서 피지(sebum)를 과잉생성하는 주원인 물질로 작용한다. 상기의 기전에 의하여 피지가 비정상적으로 과잉생성 또는 분비되면 피지관련 질환(여드름, 탈모, 지루성 피부염)을 일으키게 된다. 결과적으로 남성형 탈모, 여드름, 지루성피부염 등 남성 호르몬 의존성 질환은 5α-환원효소의 작용에 의한 디히드로테스토스테론의 과잉생성 때문이며, 5α-환원효소의 활성을 억제한다면 상기의 질환을 근본적이고 효과적으로 예방하고 치료할 수 있을 것이다.Briefly explaining the action of male hormones in connection with the sebum production mechanism is as follows. Testosterone, one of the male hormones, is converted to dihydrotestosterone, an active male hormone, by 5α-reductase. The abnormal hyperactivity of this hormone acts as a substance that causes male hair loss and at the same time sebum It acts as a major source of overproduction of sebum in sebocytes. If the sebum is abnormally overproduced or secreted by the above mechanism, sebum-related diseases (acne, hair loss, seborrheic dermatitis) are caused. As a result, male hormone-dependent diseases such as male hair loss, acne, and seborrheic dermatitis are due to the overproduction of dehydrotestosterone by the action of 5α-reductase. Could be.
이러한 여드름, 남성형 탈모, 지루성피부염 등 남성호르몬 의존형 질환을 예방하고 치료하기 위하여, 현재까지 5α-환원효소의 활성을 억제하려는 많은 연구가 보고되어 왔고(Yasuro Sugimoto 외 3인; Cations Inhibit Specifically Type Ⅰ 5α-Reductase Found in Human Skin,J. Invest. Dermatol, 104, 775-778, 1995), 이에 따라 몇몇 물질들이 발견되고 있으나, 그 효과가 미미하고 피부에 대한 안전성이 부족하여 실용성이 적다는 문제점이 있다.In order to prevent and treat male hormone-dependent diseases such as acne, androgenetic alopecia and seborrheic dermatitis, many studies have been reported to inhibit the activity of 5α-reductase (Yasuro Sugimoto et al. 3; Cations Inhibit Specific Type I 5α). -Reductase Found in Human Skin, J. Invest.Dermatol, 104, 775-778, 1995), but some substances have been discovered, but the effects are insignificant and the practicality is insufficient due to lack of safety on the skin. .
한편 대한민국 출원번호 제 1999-034697호는 울금 추출물을 함유하는 화장료 조성물에 대하여 개시하고 있으나, 이는 울금의 덩이뿌리에서 추출된 추출물을 함유하며, 자유라디칼 소거 효과가 있는 피부 노화방지용 화장료 조성물에 대하여만 개시하고 있다.On the other hand, the Republic of Korea Application No. 1999-034697 discloses a cosmetic composition containing turmeric extract, which contains an extract extracted from the tuber of turmeric, only for the anti-aging cosmetic composition having a free radical scavenging effect It is starting.
따라서, 여드름, 남성형 탈모, 지루성피부염 등 남성호르몬 의존형 질환에 대한 예방 및 치료 효과가 우수하며, 피부에 안전하고 용이하게 적용할 수 있는 조성물에 대한 개발이 필요한 실정이다.Therefore, it is necessary to develop a composition that is excellent in the prevention and treatment of male hormone-dependent diseases such as acne, male hair loss, seborrheic dermatitis, and can be safely and easily applied to the skin.
상기 종래기술의 문제점을 해결하기 위하여 본 발명은 5α-환원효소에 대한 강력한 활성 억제 작용으로 디히드로테스토스테론의 생산을 효과적으로 억제할 수 있을 뿐만 아니라 피부에 안전한 울금 추출물을 포함하는 남성호르몬 의존형 피부질환 예방 및 치료용 조성물을 제공하는 것을 목적으로 한다.In order to solve the problems of the prior art, the present invention can effectively inhibit the production of dihydrotestosterone as a potent inhibitory effect on 5α-reductase, and also prevents male hormone-dependent skin diseases including turmeric extract which is safe for skin. And it aims to provide a composition for treatment.
상기 목적을 달성하기 위하여 본 발명은 울금 추출물을 포함하는 남성호르몬 의존형 피부질환의 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the prevention and treatment of male hormone-dependent skin disease comprising turmeric extract.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 남성호르몬 의존성 피부질환의 근본적 원인인 활성 남성호르몬(디히드로테스토스테론)의 생성을 억제하기 위한 방법으로 생성에 직접적으로 관여하는 5α-환원효소의 활성을 강력히 억제하며, 장시간 사용해도 안전성이 높은 물질을 개발하기 위하여 각종 천연물을 대상으로 체계적인 연구를 추진한 결과, 낮은 농도에서 울금 추출물이 5α-환원효소의 활성을 강력히 억제함을 확인하고, 이를 토대로 본 발명을 완성하게 되었다.The present inventors strongly inhibit the activity of 5α-reductase, which is directly involved in the production of a method for inhibiting the production of active male hormone (dihydrotestosterone), which is a fundamental cause of male hormone-dependent skin diseases, and is safe for long-term use. As a result of pursuing systematic research on various natural products to develop high materials, it was confirmed that turmeric extract strongly inhibits the activity of 5α-reductase at a low concentration, and completed the present invention based on this.
본 발명의 울금(鬱金,Curcumal longa)은 생강과(Zingiberaceae)에 속하는 여러해살이풀로, 우리나라에서는 을금(乙金), 걸금(乞金), 옥금(玉金), 왕금(王金), 심황(深黃)이라고도 부르며, 북부의 산악지대를 제외한 각지에서 재배한다. 주성분으로는 커큐미노이드(curcuminoids)가 15 %정도이며, 이 중에서 커큐민(curcumin, diferuloylmethane)이 가장 많이 함유되어 있고, 그 외에 디카페오일메탄(dicaffeoylmethane)과 카페오일페룰오일메탄(cafferoylferuloymethane)이 있다. 또한 정유는 약 15 %로써 세스퀴테르펜(sesquiterpene)과 세스퀴테르펜 알콜(sesquiterpene alcohol)이 함유되어 있다. 울금 중의 커큐민은 포도상구균(Staphylococcus)에 대하여 항균작용을 하며, 파라-톨릴메틸 카르비놀(PTMC: para-tolylmethyl carbinol)은 담즙분비 촉진효과가 있을 뿐 아니라, 간장질환에도 유효하다는 보고가 있다. 지용성 성분으로는 캄페스테롤(campesterol), 스티그마스테롤(stigmasterol), β-시토스테롤(sitosterol), 콜레스테롤(cholesterol) 등이 있다. 현재까지 보고된 울금의 약리효과로는 담분비촉진, 간장병, 담즙병 등이 있으며, 방향성 건위제, 카타르성 담석증, 이뇨, 이담효과, 간장의 해독기능을 촉진시키는 작용이 있다고 알려져 있다. 또한 한방에서는 뿌리줄기를 강황, 덩이뿌리를 울금이라고 하며, 강황을 건위약, 통경약으로 사용해왔고, 코피, 피오줌, 토혈에 사용한다. Curcumal longa of the present invention is a perennial herb belonging to the family of Ginger (Zingiberaceae), and in Korea, Eum gold, Gumgeum, jade gold, Wanggeum, and turmeric Also called (深 黃), it is cultivated in all parts of the country except the northern mountainous region. The main ingredient is about 15% curcuminoids, of which curcumin (diferuloylmethane) is the most abundant, and there are also decaffeoylmethane and caffeoylferuloylmethane. . The essential oil is about 15% sesquiterpene and sesquiterpene alcohol. Curcumin in turmeric has antimicrobial activity against Staphylococcus, and para-tolylmethyl carbinol (PTMC) has been reported to be effective for hepatic diseases as well as promoting bile secretion. Fat-soluble components include campesterol, stigmasterol, β-sitosterol, cholesterol, and the like. The pharmacological effects of turmeric reported to date include bile secretion promotion, hepatic disease, bile disease, and it is known that it has an effect of stimulating the detoxification function of the odorant, catarrhal cholelithiasis, diuretic, dipharyngeal effect. In addition, the root stem is called turmeric, tuber root is turmeric, and turmeric has been used as a placebo and pain medication, and it is used for nosebleeds, pisces, and blood.
상기 울금 추출물은 먼저 울금 뿌리를 정제하고 분말화하여 약 10 배량의 추출용매에서 5 일간 냉침한 후, 추출 원액을 여과, 농축, 및 동결건조하는 통상의 방법으로 분리할 수 있다. 이때 사용될 수 있는 추출 용매로는 정제수, 메탄올,에탄올, 프로판올, 부탄올, 그리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜, 메틸아세테이트, 에틸아세테이트, 벤젠, 핵산, 디에틸에테르, 및 디클로로메탄으로 이루어진 군으로부터 선택되는 1 종 또는 2 종 이상의 용매를 혼합하여 추출하거나, 1 종의 용매를 사용하여 추출한 후, 여기에 1 종 또는 2 종 이상의 용매를 사용하여 용매분획할 수 있다.The turmeric extract is first purified and powdered turmeric root and cooled in about 10 times the amount of the extraction solvent for 5 days, and then the extract can be separated by the usual method of filtration, concentration, and lyophilization. Extraction solvents that may be used include purified water, methanol, ethanol, propanol, butanol, gglycerol, propylene glycol, 1,3-butylene glycol, methyl acetate, ethyl acetate, benzene, nucleic acid, diethyl ether, and dichloromethane. One or more solvents selected from the group consisting of two or more solvents may be mixed and extracted, or one or two solvents may be used for extraction, followed by solvent fractionation using one or two or more solvents.
상기와 같이 추출한 본 발명의 울금 추출물은 추출 용매에 따라 0.01 내지 99 중량%의 커큐미노이드를 포함한다. 또한 상기 울금 추출물은 디히드로테스토스테론의 비정상적인 과잉 작용을 일으키는 원인이 되는 5α-환원효소(reductase)의 활성을 억제하여, 여드름, 남성형 탈모, 지루성피부염 등 남성호르몬 의존형 피부질환의 예방 및 치료에 매우 효과적이다.Turmeric extract of the present invention extracted as described above comprises 0.01 to 99% by weight of curcuminoids depending on the extraction solvent. In addition, the turmeric extract inhibits the activity of 5α-reductase, which causes abnormal hyperactivity of dihydrotestosterone, and is very effective in preventing and treating male hormone-dependent skin diseases such as acne, male hair loss and seborrheic dermatitis. to be.
상기와 같이 제조된 울금 추출물은 통상의 첨가제를 가하여 통상의 방법으로 화장료, 세안제, 피부외용연고 등의 조성물로 제조될 수 있다.The turmeric extract prepared as described above may be prepared by adding a conventional additive to a composition such as cosmetics, face wash, and skin ointment.
본 발명의 울금 추출물은 상기 화장료, 세안제, 피부외용연고 등의 조성물 전체에 대하여 0.01 내지 10 중량%로 포함되는 것이 바람직하다. 상기 울금 추출물의 함유량이 0.01 중량% 미만일 경우에는 남성호르몬 의존형 피부질환의 예방 및 치료 효과가 미미하고, 10 중량%를 초과할 경우에는 제조시 작업성이 떨어지며, 제조 후에도 안정화에 어려움이 있고, 첨가량의 증가에 따른 효과의 증가가 미미하여 경제적인 면에서도 사용하기 부적절한 문제점이 있다.Turmeric extract of the present invention is preferably contained in an amount of 0.01 to 10% by weight based on the entire composition, such as cosmetics, face wash, skin external ointment. When the content of the turmeric extract is less than 0.01% by weight, the prevention and treatment effect of male hormone-dependent skin disease is insignificant, and when the content of the turmeric extract exceeds 10% by weight, the workability during manufacturing is low, and there is difficulty in stabilization even after the preparation, There is a problem that is not appropriate to use economically because the increase of the effect of the increase of the small.
상기 화장료 조성물은 피부에 사용하는 것으로서, 기초 화장료 형태, 색조 화장료 형태, 또는 두발용 화장료 형태로 제조할 수 있으며, 이들 각 제형에 적합하고 당업계에 주지된 각종의 통상적인 담체와 첨가제를 포함할 수 있다.The cosmetic composition, which is used on the skin, may be prepared in the form of a basic cosmetic, a color cosmetic, or a cosmetic for hair, and may include various conventional carriers and additives suitable for each of these formulations and well known in the art. Can be.
또한 상기 세안제 조성물은 일반 세안제 베이스에 울금 추출물을 향료와 함께 혼합시키는 통상의 방법에 의하여 제조할 수 있으며, 필요에 따라 색소, 살균제, 소염제, 산화방지제, 방부제 등을 추가할 수 있고, 물성 개선을 위해 무기염류 및 합성고분자 물질을 사용할 수도 있다. 또한 상기와 같이 제조된 세안제는 고상, 액상, 크림상, 페이스트상, 패드상 등 어떠한 제형으로든 제조할 수 있다.In addition, the face wash composition may be prepared by a common method of mixing turmeric extract with a perfume on a general face wash base, can be added a pigment, fungicide, anti-inflammatory, antioxidant, preservatives, etc., if necessary, to improve the physical properties Inorganic salts and synthetic polymer materials may also be used. In addition, the face wash prepared as described above may be prepared in any formulation such as solid, liquid, cream, paste, pad.
또한 상기 피부외용연고 조성물은 통상의 방법에 의하여 제조할 수 있다.In addition, the skin external ointment composition can be prepared by a conventional method.
본 발명의 울금 추출물을 포함하는 남성호르몬 의존형 피부질환의 예방 및 치료용 조성물은 남성형 탈모, 여드름, 지루성피부염이 있는 피부에 뛰어난 효과와 안전성이 있으며, 특히 여드름이 있는 피부에 사용시 그 효과가 더욱 우수하다.The composition for the prevention and treatment of male hormone-dependent skin diseases comprising turmeric extract of the present invention has excellent effects and safety on male hair loss, acne, seborrheic dermatitis, especially when used on acne-prone skin Do.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 본 발명이 하기의 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are provided only to more easily understand the present invention, and the present invention is not limited to the following examples.
[실시예]EXAMPLE
실시예 1. 5α-환원효소 억제율 평가Example 1. Evaluation of 5α-Reductase Inhibition Rate
울금 추출물의 5α-환원효소 활성 억제율을 측정하기 위하여, 8∼10 주령의 Sprague-Dawley 쥐의 간으로부터 5α-환원효소를 얻었으며, 단백질 정량을 통하여 일정량의 단백질 현탁액(protein suspension)을 준비하였다. 또한 일반적인 방법으로 효소반응용액(enzyme reaction solution)을 준비하였으며, 5α-환원효소의 반응 기질(substrate)로는 방사선 표지(radio labeled)된 테스토스테론(3Htestosterone)을 사용하였다.In order to measure the inhibition rate of 5α-reductase activity of turmeric extract, 5α-reductase was obtained from livers of 8 to 10 weeks old Sprague-Dawley rats, and a certain amount of protein suspension was prepared by protein quantification. In addition, an enzyme reaction solution was prepared by a general method, and radiolabeled testosterone (3Htestosterone) was used as a reaction substrate of 5α-reductase.
또한 울금 뿌리를 정제하고 분말화하여 10 배량의 정제수에 넣고 약 20 ℃에서 5 일간 냉침하여 추출한 후, 이를 300 메쉬(mesh) 여과포로 여과하였다. 이를 10 ℃에서 10 일 동안 방치하여 저온 숙성시키고 여과한 후, 60 ℃로 감압 농축하고 건조하여 분리하였다.In addition, the turmeric root was purified and powdered and placed in 10 times the amount of purified water and extracted by cooling for 5 days at about 20 ℃, which was filtered with a 300 mesh (filter) filter cloth. The mixture was left at 10 ° C. for 10 days, aged at low temperature, filtered, concentrated under reduced pressure at 60 ° C., and dried.
상기 울금 추출물의 농도를 0.1 %, 0.01 %, 0.001 %, 0.0001 %로 하여 효소반응용액 : 단백질현탁액 : 울금추출물 = 70 : 20 : 20의 비율로 2 분간 항온조(incubator)에서 반응시킨 후, 반응 용매를 날려보내고 남은 물질을 전개용매에 녹여 박층크로마토그램(TLC)에 전개하였다. 전개된 테스토스테론의 양과 디히드로테스토스테론의 양을 덴시토미터(densitometer)를 이용하여 정량분석하였으며, 5α-환원효소에 의한 테스토스테론에서 디히드로테스토스테론으로의 전환율(conversion rate)을 측정하여 그 결과를 대조군(울금추출물을 첨가하지 않았을 때의 전환율)과 비교하여 하기 표 1에 나타내었다. 억제율은 하기의 계산식에 따라 계산하였다.After the concentration of the turmeric extract is 0.1%, 0.01%, 0.001%, 0.0001%, the enzyme reaction solution: protein suspension: turmeric extract = 70: 20: 20, reacted in an incubator for 2 minutes, the reaction solvent Was blown and the remaining material was dissolved in a developing solvent and developed on a thin layer chromatography (TLC). The amount of testosterone developed and the amount of dihydrotestosterone were quantitatively analyzed using a densitometer. Conversion rate when no turmeric extract is added) is shown in Table 1 below. Inhibition rate was calculated according to the following formula.
[계산식][formula]
A : 추출물 미첨가시 테스토스테론에서 디히드로테스토스테론으로의 전환율A: Conversion rate of testosterone to dihydrotestosterone when no extract is added
B : 추출물 첨가시 테스토스테론에서 디히드로테스토스테론으로의 전환율B: Conversion rate of testosterone to dihydrotestosterone upon addition of extract
상기 표 1을 통하여, 울금 추출물이 5α-환원효소의 활성을 강력히 억제함을 알 수 있었다.Through Table 1, it was found that turmeric extract strongly inhibits the activity of 5α-reductase.
실시예 2∼5 및 비교예 1. 세안제 제조Examples 2 to 5 and Comparative Example 1. Preparation of face wash
세안제 베이스(수분 포함)와 상기 실시예 1에서 분리한 0.1 %의 울금 추출물을 하기 표 2와 같은 조성으로 호모믹서기에 넣은 후, 이를 교반하고 가열한 후, 탈기 및 냉각 등의 과정을 거쳐 조성 물질이 균일하게 혼합되도록 하여 울금 추출물을 포함하는 세안제를 제조하였다.After the cleanser base (containing water) and 0.1% turmeric extract isolated in Example 1 was added to a homomixer with a composition as shown in Table 2 below, the mixture was stirred and heated, and then degassed and cooled to obtain a composition material. This was mixed uniformly to prepare a face wash containing turmeric extract.
실시예 6. 여드름 예방 및 치료 효과Example 6 Acne Prevention and Treatment Effect
상기 실시예 2 내지 5, 및 비교예 1에서 제조된 세안제의 여드름 예방 및 치료에 관한 임상 효과를 측정하기 위하여, 10 대 후반∼20 대 후반의 지원자를 각 군 당 20 명씩 되도록 구분한 뒤, 1 일 3 회씩 한 달 동안 사용하도록 하였다.In order to measure the clinical effect of the acne prevention and treatment of the facial cleanser prepared in Examples 2 to 5, and Comparative Example 1, after dividing the number of volunteers in the late teens to late 20s to 20 people in each group, 1 It was used three times a day for one month.
판정 방법은 임상시험 시작 전과 후에 각각 여드름의 상태를 등급화한 후,그 차이의 정도를 하기 표 3의 기준으로 판정하였다.As for the determination method, the condition of acne was graded before and after the start of the clinical trial, respectively, and the extent of the difference was determined based on the criteria of Table 3 below.
또한 임상시험 대상자의 여드름에 대한 등급이 시험 전에 비하여 3 등급 이상의 감소를 나타내면 효과 우수, 1∼2 등급의 감소를 나타내면 효과 중간, 감소가 나타나지 않으면 효과 없음, 시험 전의 등급보다 시험 후의 등급이 높으면 악화되는 것으로 판정하였고, 그 결과를 하기 표 4에 나타내었다.In addition, if the grade of acne of the clinical trial subjects shows a reduction of 3 or more levels before the test, the effect is excellent; if the decrease is 1 to 2 grades, the effect is moderate; if the decrease does not appear, the effect is not higher. It was determined that the result, and the results are shown in Table 4.
상기 표 4을 통하여, 실시예 2 내지 5의 울금 추출물을 포함하는 세안제가 비교예 1의 울금 추출물을 함유하지 않은 것과 비교하여 여드름 치료 효과가 우수할 뿐만 아니라, 피부발적 등의 부작용도 나타나지 않음을 확인할 수 있었다.Through Table 4, the facial cleansing agent containing the turmeric extracts of Examples 2 to 5 is not only excellent in the acne treatment effect compared to that containing no turmeric extract of Comparative Example 1, and also does not show side effects such as skin redness. I could confirm it.
본 발명에 따르면, 울금 추출물을 포함하는 조성물은 5α-환원효소에 의한 디히드로테스토스테론의 과잉생산을 억제하여 여드름, 남성형 탈모, 지루성피부염 등 남성호르몬 의존형 피부질환의 예방 및 치료에 뛰어난 효과가 있다.According to the present invention, the composition containing turmeric extract has an excellent effect on the prevention and treatment of male hormone-dependent skin diseases such as acne, male hair loss, seborrheic dermatitis by inhibiting the excessive production of dihydrotestosterone by 5α-reductase.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020021590A KR20030083159A (en) | 2002-04-19 | 2002-04-19 | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020021590A KR20030083159A (en) | 2002-04-19 | 2002-04-19 | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030083159A true KR20030083159A (en) | 2003-10-30 |
Family
ID=32379722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020021590A KR20030083159A (en) | 2002-04-19 | 2002-04-19 | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030083159A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100891986B1 (en) | 2007-08-23 | 2009-04-08 | 최진일 | Cosmetic composition containing herb medicine extracts and powders |
KR100899278B1 (en) * | 2007-10-15 | 2009-05-26 | 보령메디앙스 주식회사 | Cosmetic composition |
KR20160011415A (en) | 2014-07-22 | 2016-02-01 | (주) 나노 카보나 | Cosmetic Composition Containing Herb Medicine Extracts and Powders |
KR20160011414A (en) | 2014-07-22 | 2016-02-01 | (주) 나노 카보나 | Cosmetic Composition Containing Herb Medicine Extracts and Powders |
US20170239313A1 (en) * | 2014-10-14 | 2017-08-24 | Biocogent, Llc | Compositions and methods comprising extracts of zingiberaceae |
KR20220124390A (en) * | 2021-03-03 | 2022-09-14 | (주)대한뷰티산업진흥원 | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract |
-
2002
- 2002-04-19 KR KR1020020021590A patent/KR20030083159A/en not_active Application Discontinuation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100891986B1 (en) | 2007-08-23 | 2009-04-08 | 최진일 | Cosmetic composition containing herb medicine extracts and powders |
KR100899278B1 (en) * | 2007-10-15 | 2009-05-26 | 보령메디앙스 주식회사 | Cosmetic composition |
KR20160011415A (en) | 2014-07-22 | 2016-02-01 | (주) 나노 카보나 | Cosmetic Composition Containing Herb Medicine Extracts and Powders |
KR20160011414A (en) | 2014-07-22 | 2016-02-01 | (주) 나노 카보나 | Cosmetic Composition Containing Herb Medicine Extracts and Powders |
US20170239313A1 (en) * | 2014-10-14 | 2017-08-24 | Biocogent, Llc | Compositions and methods comprising extracts of zingiberaceae |
CN107405374A (en) * | 2014-10-14 | 2017-11-28 | 比奥考金特有限责任公司 | Composition and method comprising Zingiber extract |
KR20220124390A (en) * | 2021-03-03 | 2022-09-14 | (주)대한뷰티산업진흥원 | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR980008238A (en) | Composition having inhibitory activity of 5α-reductase and antimicrobial activity on propionibacterium acnes | |
JP2007001914A (en) | Skin barrier function-improving agent | |
KR102062854B1 (en) | Cosmetic composition containing active fractions of Rubus coreanus MIQ root | |
KR101287052B1 (en) | Testosterone 5alpha-reductase inhibitor containing elsholtziae herba extract | |
KR20030083159A (en) | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract | |
JP4866501B2 (en) | Topical skin preparation | |
JPH04346911A (en) | Cosmetic | |
KR100879094B1 (en) | Cosmetics formulation containing natural essential oils and its hydrosols | |
JPH08310923A (en) | Testosterone 5alpha-reductase inhibitor | |
JP4033981B2 (en) | Testosterone 5α-reductase inhibitor | |
JP2003095858A (en) | Skin care preparation | |
JP5184813B2 (en) | Collagen production promotion and degradation inhibitor | |
JP2007191452A (en) | Estrogen-like active agent | |
JPS6293217A (en) | Hair tonic | |
JPH1171234A (en) | Skin preparation for external use | |
JPH04346912A (en) | Cosmetic | |
JPH049313A (en) | Cosmetic | |
JP3647296B2 (en) | Inhibition of tyrosinase activity and compositions containing the same | |
KR19990055304A (en) | 5α-reductase activity inhibiting composition containing cloves | |
JPH11124325A (en) | Serine protease inhibitor | |
KR20020050411A (en) | The compositions inhibiting 5 alpha-reductase activity | |
KR20050079377A (en) | Compositions containing the extract of sanguisorba officinalis, which has the inhibitor activity against 5 alpha reductase | |
JP3799151B2 (en) | Topical skin preparation | |
JP4803698B2 (en) | Anti-aging agent, estrogenic agent, anti-androgen agent, hair restorer, testosterone 5α-reductase inhibitor, skin cosmetic and hair cosmetic | |
JPH08175964A (en) | Skin preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |